Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Merrill

Showing results (281-290 of 414) with videos related to

Pageof 42
Sort By:
Lancet (London, England)|August 21, 2016
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trialQuan Dong Nguyen, Pauline T Merrill, Glenn J Jaffe, et al.
Plos One|February 12, 2015
Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpuraContessa E Edgar, Deirdra R Terrell, Sara K Vesely, et al.
Arthritis Research & Therapy|August 21, 2015
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trialsWilliam Stohl, Joan T Merrill, R John Looney, et al.
Arthritis Care & Research|January 25, 2017
Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and ControlsTeresa Aberle, Rebecka L Bourn, Melissa E Munroe, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 13, 2017
Kidney Outcomes and Risk Factors for Nephritis (Flare/<i>De Novo</i>) in a Multiethnic Cohort of Pregnant Patients with LupusJill P Buyon, Mimi Y Kim, Marta M Guerra, et al.
Eclinicalmedicine|March 11, 2020
Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional studyJoel M Guthridge, Rufei Lu, Ly Thi-Hai Tran, et al.
Lancet (London, England)|May 29, 2026
Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trialMegan E B Clowse, David A Isenberg, Joan T Merrill, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 11, 2016
Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With TabalumabRobert W Hoffman, Joan T Merrill, Marta M E Alarcón-Riquelme, et al.
American Journal of Obstetrics and Gynecology|October 4, 2015
Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE studyMimi Y Kim, Jill P Buyon, Marta M Guerra, et al.
Genes and Immunity|May 15, 2009
Evaluation of C1q genomic region in minority racial groups of lupusB Namjou, C Gray-McGuire, A L Sestak, et al.
Pageof 42

Showing results (281-290 of 414) with videos related to

Sort By:
Pageof 42
Lancet (London, England)|August 21, 2016
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trialQuan Dong Nguyen, Pauline T Merrill, Glenn J Jaffe, et al.
Plos One|February 12, 2015
Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpuraContessa E Edgar, Deirdra R Terrell, Sara K Vesely, et al.
Arthritis Research & Therapy|August 21, 2015
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trialsWilliam Stohl, Joan T Merrill, R John Looney, et al.
Arthritis Care & Research|January 25, 2017
Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and ControlsTeresa Aberle, Rebecka L Bourn, Melissa E Munroe, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 13, 2017
Kidney Outcomes and Risk Factors for Nephritis (Flare/<i>De Novo</i>) in a Multiethnic Cohort of Pregnant Patients with LupusJill P Buyon, Mimi Y Kim, Marta M Guerra, et al.
Eclinicalmedicine|March 11, 2020
Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional studyJoel M Guthridge, Rufei Lu, Ly Thi-Hai Tran, et al.
Lancet (London, England)|May 29, 2026
Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trialMegan E B Clowse, David A Isenberg, Joan T Merrill, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 11, 2016
Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With TabalumabRobert W Hoffman, Joan T Merrill, Marta M E Alarcón-Riquelme, et al.
American Journal of Obstetrics and Gynecology|October 4, 2015
Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE studyMimi Y Kim, Jill P Buyon, Marta M Guerra, et al.
Genes and Immunity|May 15, 2009
Evaluation of C1q genomic region in minority racial groups of lupusB Namjou, C Gray-McGuire, A L Sestak, et al.
Pageof 42